ESSA Pharma Inc

XenoTherapeutics has completed the acquisition of ESSA Pharma and acquired all outstanding common shares through its subsidiary Xeno Acquisition Corp. for about $0.1242 per share. The previously revised terms were supplemented by a contingent value right (CVR) that can enable additional payments of up to $0.14 per share and up to $6.7 million in total. The acquisition was approved by the Supreme Court of British Columbia; ESSA has applied to delist from Nasdaq and plans an $80 million liquidation distribution to shareholders. » More on de.investing.com

Holders of ESSA Pharma securities voted by an overwhelming majority (99.83% and 99.85% including options/warrants) to approve the takeover by XenoTherapeutics under a plan of arrangement. The transaction remains subject to court approval by the Supreme Court of British Columbia; the hearing is scheduled for October 7, 2025, and closing is expected around October 9, 2025. ESSA announced amended deal terms: the expected cash payment was reduced from 1.91 USD to about 0.12 USD per share, and shareholders will also receive a non-transferable CVR with a possible payment of up to 0.14 USD; additionally, an $80 million distribution to shareholders is planned. Shareholders also provisionally approved a voluntary liquidation in case the takeover fails and voted to approve the transaction-related compensation for executives. » More on de.investing.com

The Supreme Court of British Columbia approved the rescheduling of ESSA Pharma’s extraordinary general meeting to Oct. 3, 2025 as an online webcast; stakeholders can object until Oct. 1, and court approval of the deal is set for Oct. 7. XenoTherapeutics is to acquire all issued common shares of ESSA, but the merger terms were revised: the expected cash payout was cut from about $1.91 to roughly $0.12 per share and a non‑transferable CVR worth up to $0.14 was added. ESSA plans an $80m distribution to shareholders (payment date Aug. 22) and the acquisition financing comes from XOMA Royalty Corporation. The micro‑cap stock is trading near its 52‑week low and is down 74% year to date. » More on de.investing.com